Detailed View
CRVS - Corvus Pharmaceuticals, Inc.
Latest filing: 2026-03-31 | Reporting: gaap
Market Cap
1,150,356,992
Adj EBIT (TTM)
-47,926,000
Enterprise Value
1,110,254,992
Last Price
13.68
Earnings Yield
-4.32%
Return on Capital
-19.88%
Capital
241,085,000
1Y Price Chart
Last Price: -
1Y Change: -
Company Summary
Loading summary...
| endDate | formType | fiscalYear | Revenue | OperatingIncomeLoss |
|---|---|---|---|---|
| 2026-03-31 | 10-Q | 2026 | 0 | -14,877,000 |
| 2025-12-31 | 10-K (Q4 derived) | 2025 | 0 | -12,217,000 |
| 2025-09-30 | 10-Q | 2025 | 0 | -10,572,000 |
| 2025-06-30 | 10-Q | 2025 | 0 | -10,260,000 |
| 2025-03-31 | 10-Q | 2025 | 0 | -9,922,000 |
| 2024-12-31 | 10-K (Q4 derived) | 2024 | 0 | -8,105,000 |
| 2024-09-30 | 10-Q | 2024 | 0 | -7,255,000 |
| 2024-06-30 | 10-Q | 2024 | 0 | -5,935,000 |
Notice something wrong?
Submit a quick report with a snapshot of the values you are seeing.